These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 9138325)

  • 1. [Ambulatory treatment and prevention of priapism using alpha-agonists. Apropos of 172 cases].
    Virag R; Bachir D; Floresco J; Galacteros F; Dufour B
    Chirurgie; 1997 Jan; 121(9-10):648-52. PubMed ID: 9138325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Management of priapism in sickle-cell diseases with alpha-adrenergic agonists].
    Gbadoé AD; Koffi KS; Akakpo-Maxwell O; Lawson-Evi K; Guédéhoussou T; Assimadi JK
    Sante; 2002; 12(3):343-7. PubMed ID: 12473531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Sickle cell disease priapism: treatment with intracavernous injections of etilefrine].
    Gbadoe AD; Akakpo-Vidah A; Pitche P; Assimadi JK
    Med Trop (Mars); 2000; 60(1):53-6. PubMed ID: 10989788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prevention and treatment of erectile disorders in sickle cell disease].
    Bachir D; Virag R; Lee K; Belloy M; de Montalembert M; Denis L; Broyart A; Girot R; Galactéros F
    Rev Med Interne; 1997; 18 Suppl 1():46s-51s. PubMed ID: 9183463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prevention of prolonged drug-induced erection by intracavernous injection of etilefrine].
    Fiter Gómez L; Herrero Payo A; Mejías Callaved J; Gimeno Albo F
    Actas Urol Esp; 1997 Feb; 21(2):128-32. PubMed ID: 9214209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preventive treatment of priapism in sickle cell disease with oral and self-administered intracavernous injection of etilefrine.
    Virag R; Bachir D; Lee K; Galacteros F
    Urology; 1996 May; 47(5):777-81; discussion 781. PubMed ID: 8650886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chart for preparation of dilutions of alpha-adrenergic agonists for intracavernous use in treatment of priapism.
    Lee M; Cannon B; Sharifi R
    J Urol; 1995 Apr; 153(4):1182-3. PubMed ID: 7869493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Intracavernous injection of etilefrine hydrochloride in iatrogenic priapism].
    Uchida T; Omata T; Koshiba K
    Hinyokika Kiyo; 1986 Dec; 32(12):1879-82. PubMed ID: 2881462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of sickle cell priapism with etilefrine.
    Gbadoé AD; Atakouma Y; Kusiaku K; Assimadi JK
    Arch Dis Child; 2001 Jul; 85(1):52-3. PubMed ID: 11420201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Metaraminol in therapy of various forms of priapism].
    Block T; Sturm W; Ernst G; Staehler G; Schmiedt E
    Urologe A; 1988 Jul; 27(4):225-9. PubMed ID: 3140463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Follow-up of sickle cell disease patients with priapism treated by hydroxyurea.
    Saad ST; Lajolo C; Gilli S; Marques Júnior JF; Lima CS; Costa FF; Arruda VR
    Am J Hematol; 2004 Sep; 77(1):45-9. PubMed ID: 15307105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etilefrine for the prevention of priapism in adult sickle cell disease.
    Okpala I; Westerdale N; Jegede T; Cheung B
    Br J Haematol; 2002 Sep; 118(3):918-21. PubMed ID: 12181066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracavernosal etilefrine self-injection therapy for recurrent priapism: one decade of follow-up.
    Teloken C; Ribeiro EP; Chammas M; Teloken PE; Souto CA
    Urology; 2005 May; 65(5):1002. PubMed ID: 15882751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral midodrine for prostaglandin e1 induced priapism in spinal cord injured patients.
    Soler JM; Previnaire JG; Mieusset R; Plante P
    J Urol; 2009 Sep; 182(3):1096-100. PubMed ID: 19616810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Medical treatment of venous priapism apropos of 46 cases: puncture, pharmacologic detumescence or penile cooling?].
    Bondil P; Descottes JL; Salti A; Sabbagh R; Hamza T
    Prog Urol; 1997 Jun; 7(3):433-41. PubMed ID: 9273072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of priapism lasting 24 hours or longer caused by intracavernosal injection of vasoactive drugs.
    Kulmala RV; Tamella TL
    Int J Impot Res; 1995 Jun; 7(2):131-6. PubMed ID: 7496442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Intracavernous injections of etilefrin: its efficacy in the treatment of priapism in sickle cell patients].
    Gbadoé AD; Akakpo-Vidah A; Tsolényanu E; Messie K; Atakouma DY; Ségbéna AY; Vovor A; Tékou HA; Assimadi JK
    Presse Med; 1999 Jul 3-10; 28(24):1283-6. PubMed ID: 10442057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The incidence and management of priapism in Western Australia: a 16 year audit.
    Earle CM; Stuckey BG; Ching HL; Wisniewski ZS
    Int J Impot Res; 2003 Aug; 15(4):272-6. PubMed ID: 12934055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergency evaluation and treatment of priapism.
    Vilke GM; Harrigan RA; Ufberg JW; Chan TC
    J Emerg Med; 2004 Apr; 26(3):325-9. PubMed ID: 15028333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Methylene blue: an effective therapeutic alternative for priapism induced by intracavernous injection of vasoactive agents].
    Martínez Portillo FJ; Fernández Arancibia MI; Bach S; Alken P; Jünemann KP
    Arch Esp Urol; 2002 Apr; 55(3):303-8. PubMed ID: 12068762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.